Leveraging traditional and advanced machine learning for comprehensive oncology data integration and outcome prediction.

Authors

Grace Hey, Michael Del Sesto, Megan Still, Gopi Patel, Nellie Crlenjak, Abeer Dagra, Yonghui Wu, Yi Guo, Ashley P Ghiaseddin

Published in

Journal of neuro-oncology. Volume 180. Issue 1. Oct 12, 2026. Epub Oct 12, 2026.

Abstract

Outcome prediction in neuro-oncology remains challenging due to heterogeneity in tumor biology, imaging characteristics, treatment response, and patient-specific clinical factors. Although molecular databases have advanced understanding of brain tumor biology, many datasets lack broader data necessary for generalizable predictive modeling. Artificial intelligence (AI) and machine learning (ML) are increasingly being explored to integrate these heterogeneous data sources and support precision neuro-oncology.
A narrative review was performed using PubMed and Embase to identify studies evaluating oncology databases, ML models, multimodal data integration, and AI applications relevant to neuro-oncology. Studies published between 2020 and 2026 were preferentially reviewed, with additional landmark studies included when relevant.
Traditional ML approaches including regression-based models, random forests, support vector machines, and gradient boosting algorithms have been applied to survival prediction, recurrence classification, treatment response estimation, and molecular biomarker prediction using clinical, imaging, molecular, and population-level datasets. More advanced architectures including natural language processing, large language models, vision transformers, geometric deep learning, and graph neural networks have expanded the ability to analyze unstructured and multimodal data sources including radiology reports, histopathology slides, MRI volumes, molecular datasets, and electronic health records. Multimodal AI systems integrating imaging, molecular, histopathologic, clinical, and socioeconomic data frequently demonstrated improved predictive performance compared with single-modality models. However, widespread clinical implementation remains limited by dataset heterogeneity, limited external validation, interpretability concerns, and inconsistent representation across patient populations.
AI and ML approaches are increasingly capable of integrating complex neuro-oncology datasets in ways that more closely reflect real-world clinical decision-making. Although most current models remain investigational, multimodal AI frameworks may ultimately improve prognostic assessment, treatment stratification, and precision neuro-oncology care. Continued progress will require larger representative datasets, improved data harmonization, external validation, and clinically interpretable models.

PMID:
42862479
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.